Alnylam Pharmaceuticals ALNY Q1 2025 earnings
Reported May 1, 2025 · Before market open
Revenue estimate$585.1M
EPS estimate-$0.89
Next report
Jul 30, 2026 (In 2 weeks)Revenue estimate$1.3B
EPS estimate$1.61
Financials
Q1 2025Valuation & ratios
Segments
By product
Versus estimates
Revenue
Diluted EPS
Ask the moment Alnylam Pharmaceuticals reports.
Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.
Connect your AI
Claude
Questions, answered.
- When did Alnylam Pharmaceuticals report Q1 2025 earnings?
- Alnylam Pharmaceuticals (ALNY) reported Q1 2025 earnings on May 1, 2025 before market open.
- What were Alnylam Pharmaceuticals's Q1 2025 revenue and EPS?
- Alnylam Pharmaceuticals reported revenue of $594.2M and diluted EPS of $-0.01 for Q1 2025.
- Did Alnylam Pharmaceuticals beat estimates in Q1 2025?
- Revenue beat the consensus estimate of $585.1M by $9.0M. EPS beat the consensus estimate of $-0.89 by $0.88.
- How did Alnylam Pharmaceuticals's Q1 2025 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 20.2% from $494.3M a year earlier and diluted EPS grew 93.8% from $-0.16.
- Where can I find Alnylam Pharmaceuticals's Q1 2025 SEC filings?
- You can read the 10-Q periodic report (0001178670-25-000052) directly on SEC EDGAR. The filing index links above go to sec.gov.